Rezolute Inc (RZLT) - Total Assets
Based on the latest financial reports, Rezolute Inc (RZLT) holds total assets worth $125.46 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rezolute Inc - Total Assets Trend (2012–2025)
This chart illustrates how Rezolute Inc's total assets have evolved over time, based on quarterly financial data. Also see RZLT stock market capitalisation for the company's overall valuation and market capitalisation.
Rezolute Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Rezolute Inc's total assets of $125.46 Million consist of 97.5% current assets and 2.5% non-current assets. Review RZLT total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 53.6% |
| Accounts Receivable | $700.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Rezolute Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See RZLT stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rezolute Inc's current assets represent 97.5% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 53.6% of total assets in 2025, up from 2.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Rezolute Inc Competitors by Total Assets
Key competitors of Rezolute Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Rezolute Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.84 | 8.43 | 21.34 |
| Quick Ratio | 15.84 | 8.43 | 21.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $114.34 Million | $78.21 Million | $40.02 Million |
Rezolute Inc - Advanced Valuation Insights
This section examines the relationship between Rezolute Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.86 |
| Latest Market Cap to Assets Ratio | 2.17 |
| Asset Growth Rate (YoY) | 32.2% |
| Total Assets | $175.49 Million |
| Market Capitalization | $380.35 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Rezolute Inc's assets at a significant premium (2.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Rezolute Inc's assets grew by 32.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rezolute Inc (2012–2025)
The table below shows the annual total assets of Rezolute Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $175.49 Million | +32.21% |
| 2024-06-30 | $132.74 Million | +7.29% |
| 2023-06-30 | $123.72 Million | -18.83% |
| 2022-06-30 | $152.42 Million | +257.72% |
| 2021-06-30 | $42.61 Million | +288.59% |
| 2020-06-30 | $10.96 Million | -10.50% |
| 2019-06-30 | $12.25 Million | +389.52% |
| 2018-06-30 | $2.50 Million | -76.45% |
| 2017-06-30 | $10.63 Million | -2.52% |
| 2016-06-30 | $10.90 Million | -3.19% |
| 2015-06-30 | $11.26 Million | +52.11% |
| 2014-06-30 | $7.40 Million | +570.73% |
| 2013-06-30 | $1.10 Million | +3.31% |
| 2012-06-30 | $1.07 Million | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more